Nicox, and Glaukos ink exclusive NCX 1728 research and global licensing option agreement: Sophia Antipolis, France Tuesday, September 24, 2024, 17:00 Hrs [IST] Nicox SA, an intern ...

The company believes these combinations create a broader approach to treating neurodegenerative diseases ・Preclinical studies have demonstrated these combinations significant ...

The benefits do not stop there. Recent studies suggest GLP-1 drugs may also reduce the risk of heart disease, kidney disease and stroke, and even possibly protect the brain from AD by reducing ...

Pharmaceutical companies are demonstrating innovation by not only developing new drugs but also exploring combination therapies and ...